Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

Chart & Performance

D1W1MN

P/E

24.79

P/S

0.94

EPS

1.08

Div Yield, %

2.79%

Shrs. gr., 5y

—

Rev. gr., 5y

2.92%

Revenues

74.99b

-0.69%

Net income

2.84b

-30.09%

CFO

3.44b

-16.11%

Dividend

Jun 18, 20240.749 CNY/sh

Earnings

May 29, 2025

Profile

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People's Republic of China and internationally. The company operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. It is also involved in the wholesale, retail, import, and export of Western and Chinese medicines, and medical apparatus and instruments; and research and development, production, and sale of beverages, food, healthcare products, pre-packaging food, dairy products, tablets, capsules, lozenges, injections, tortoise herb jelly, etc. In addition, the company invests in health industry, such as medical care, health management, health preservation, elderly care, etc.; and provides commercial and advertising services. As of December 31, 2021, it had 154 retail chain pharmacy outlets, which included 22 Cai Zhi Lin pharmacy outlets, 36 Jian Min pharmacy outlets, 51 GPC Prescription Pharmacy outlets, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd outlets, as well as 22 retail stores. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.

URL

http://www.gybys.com.cn/

IPO date

Oct 21, 1997

Employees

23,493

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	74,992,820 -0.69%	75,515,404 6.68%	70,788,155 2.57%
Cost of revenue	66,236,457	68,795,120	64,759,238
Unusual Expense (Income)
NOPBT	8,756,363	6,720,284	6,028,917
NOPBT Margin	11.68%	8.90%	8.52%
Operating Taxes	606,849	851,170	789,874
Tax Rate	6.93%	12.67%	13.10%
NOPAT	8,149,515	5,869,114	5,239,043
Net income	2,835,496 -30.09%	4,055,679 2.25%	3,966,522 6.63%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current	9,122,982	7,799,036	9,244,797
Long-term debt	3,696,969	4,480,103	2,730,890
Deferred revenue	1,001,862	1,001,430	930,926
Other long-term liabilities	119,613	130,894	121,764
Net debt	(5,453,199)	(18,481,467)	(16,420,817)
Cash flow
Cash from operating activities	3,442,427	4,103,625	6,999,076
CAPEX
Cash from investing activities		(3,114,859)
Cash from financing activities		(1,978,001)	45,950
FCF	3,523,170	5,537,800	4,848,936
Balance
Cash	18,273,150	21,312,844	22,556,425
Long term investments	2	9,447,761	5,840,078
Excess cash	14,523,509	26,984,835	24,857,096
Stockholders' equity	25,306,235	24,319,320	21,460,658
Invested Capital	36,741,838	25,191,774	24,284,023
ROIC	26.32%	23.73%	22.40%
ROCE	16.87%	13.40%	13.07%
EV
Common stock shares outstanding	1,625,858	1,625,791	1,625,624
Price	28.42 30.97%	21.70 -5.65%	23.00 2.45%
Market cap	46,206,881 30.97%	35,279,664 -5.64%	37,389,349 2.44%
EV	42,618,791	18,556,740	22,554,166
EBITDA	9,631,606	7,649,721	6,772,745
EV/EBITDA	4.42	2.43	3.33
Interest	418,151	446,192	434,408
Interest/NOPBT	4.78%	6.64%	7.21%